GlassScriptPhysician profile
Crystal Gaskins
NPI 1932601416
$5,219.83
in general payments reported to CMS, 2019-2025
32 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $687 · 2022: $652 · 2023: $1,516 · 2024: $1,193 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868 · Entertainment: $13.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.58 |
| Entertainment | $13.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,154.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $803.72 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $677.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.49 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $246.46 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $219.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.21 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $129.76 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $111.60 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dynavax Technologies Corporation | $108.57 | 2024-2025 | Heplisav-B |
| Corium, LLC | $98.44 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $91.99 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $86.83 | 2023-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.48 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $60.66 | 2023 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.14 | 2025 | Otezla, Repatha |
| Shield Therapeutics INC | $56.87 | 2023 | Accrufer |
| Inspire Medical Systems, INC. | $55.16 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $49.78 | 2022-2025 | Lagevrio, Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $41.21 | 2025 | |
| Xeris Pharmaceuticals, INC. | $36.34 | 2022-2024 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $34.87 | 2021-2022 | |
| Athena Bioscience, LLC | $27.42 | 2023 | Qdolo |
| Sanofi Pasteur INC. | $19.98 | 2025 | |
| Sumitomo Pharma America, INC. | $19.27 | 2025 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $17.89 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $16.84 | 2023 | Quviviq |
| Antares Pharma, INC. | $16.54 | 2023 | Xyosted, Nocdurna, Tlando |
| Currax Pharmaceuticals LLC | $15.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.52 | 2021 | |
| Optos, INC. | $13.21 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kowa Pharmaceuticals America, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Gaskins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.